PTC founder and Chief Executive Officer, Stuart Peltz, Ph.D., was recently the subject of a MassBio profile. When asked about the future of PTC, he had this to say:
PTC has been growing rapidly over the last two years and we will continue to grow and expand in the upcoming year. We plan to launch four new treatments over the next year—including our first gene therapy for the treatment of AADC deficiency—by year end. We are accelerating 20 discovery and development programs over the next five years. We will also begin manufacturing our gene therapy products in our own facility in 2020. We are expanding into new scientific platforms and therapeutic areas, including Friedreich’s Ataxia, Angelman Syndrome and Huntington’s Disease. Using our new redox scientific platform, we will also be expanding into a number of mitochondrial epilepsies and neuro-infl ammatory diseases. I’m pretty sure this is going to be another exciting year!
Dr. Peltz founded PTC in 1998 with the vision of an exciting, innovative science company for treating patients with rare diseases. Get to know more about our history and learn what’s in store for our future.